Pharmaceuticals News and Research

RSS

Bitter melon juice restricts ability of pancreatic cancer cells to metabolize glucose

A University of Colorado Cancer study published this week in the journal Carcinogenesis shows that bitter melon juice restricts the ability of pancreatic cancer cells to metabolize glucose, thus cutting the cells' energy source and eventually killing them.

13 Mar 2013

Trans-Pacific Partnership (TPP) Agreement: an interview with Judit Rius, Médecins Sans Frontières

The Trans-Pacific Partnership (TPP) is a trade deal currently being negotiated between eleven countries of the Asia-Pacific region: Australia, Brunei Darussalam, Canada, Chile, Malaysia, Mexico, New Zealand, Peru, United States, Singapore and Vietnam.

12 Mar 2013

Chimerix receives FDA Fast Track designation for CMX001 to prevent CMV infection

Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CMX001 for the prevention of cytomegalovirus (CMV) infection.

12 Mar 2013

Lithera commences LIPO-202 Phase 2b trial for reduction of subcutaneous fat

Lithera, Inc., a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and ophthalmology, announced today that the first patient has been treated with LIPO-202 (Salmeterol Xinafoate for Injection) in its 500-patient Phase 2b "RESET" trial.

12 Mar 2013

Sleep problems may be indicator of early Alzheimer's disease

Sleep is disrupted in people who likely have early Alzheimer's disease but do not yet have the memory loss or other cognitive problems characteristic of full-blown disease, researchers at Washington University School of Medicine in St. Louis report March 11 in JAMA Neurology.

12 Mar 2013

Anti-cancer drug conjugates: an interview with Dr Andreas Menrad, CSO Ablynx and Dr Chris Martin, CEO Spirogen

Antibodies and in the case of Ablynx, Nanobodies, can be raised and selected to bind with high affinity selectively to cancer cells in a tumour. Cancer cells are exquisitely sensitive to certain toxins such as the PBDs produced by Spirogen.

12 Mar 2013

Pneumococcal vaccine pre-clinical development supported by £0.2 million award from Biomedical Catalyst

ImmBio (Immunobiology Ltd), a biopharmaceutical company developing innovative vaccines against serious infectious diseases, today announced that the UK government-backed Biomedical Catalyst has awarded the company approximately £0.2 million ($0.3 million) to support pre-clinical development of its pneumococcal vaccine, PnuBioVax™, which targets a wide range of strains of the bacteria.

12 Mar 2013

Sosei commences SO-1105 Phase III trial in oropharyngeal candidiasis

Sosei Group Corporation, the biopharmaceutical company, today announces that its Japanese subsidiary, Sosei Co., Ltd., has initiated a Phase III trial for SO-1105 for the treatment of oropharyngeal candidiasis.

12 Mar 2013

FDA accepts Ampio’s Patient Outcome for Premature Ejaculation questionnaire

Ampio Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat prevalent inflammatory diseases, such as osteoarthritis (Ampion) and diabetic macular edema (Optina) and sexual dysfunction (Zertane) announced FDA acceptance of its POPE questionnaire, a modification of the Premature Ejaculation Profile (PEP) questionnaire that was used in the two successful Zertane Phase 3 clinical trials completed in Europe.

11 Mar 2013

Armetheon plans to develop tecarfarin against prosthetic heart valves or chronic renal dysfunction

Armetheon, Inc., a clinical stage biopharmaceutical company, announced today that it plans to develop its novel oral anti-coagulant (OAC), tecarfarin (ATI-5923), for a patient population which includes those who have prosthetic heart valves or chronic renal dysfunction.

11 Mar 2013

Drugs that combat ageing may be available within five years

Drugs that combat ageing may be available within five years, following landmark work led by an Australian researcher.

11 Mar 2013

Investigational treatment for ulcerative colitis (UC) and Crohn’s disease (CD) has Marketing Authorisation Application submitted

Takeda Pharmaceutical Company Limited (“Takeda”) today announced that a Marketing Authorisation Application (MAA) has been submitted to The European Medicines Agency (EMA) for vedolizumab, an investigational, gut-selective humanized monoclonal antibody for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD), the two most common types of inflammatory bowel disease (IBD).

8 Mar 2013

Animal robots help treat dementia

Proving the benefits and cost-effectiveness of animal robots in the treatment of dementia is the focus of a Griffith research study.

8 Mar 2013

Global cancer problem ‘needs international solution’

Global leaders in cancer research and policy are calling on the scientific community and worldwide governments to unite against the disease.

8 Mar 2013

UCR professor to better organize enzymes on electrodes to create nanoscale devices

An assistant professor at the University of California, Riverside's Bourns College of Engineering has recently received a $360,000 grant to better organize enzymes on electrodes to create nanoscale devices that more efficiently convert the chemical energy of sugars and complex carbohydrates in to electricity.

8 Mar 2013

Novel drug seems to increase effectiveness of usual chemotherapy against IBC

Researchers in the University of Delaware's Department of Biological Sciences are investigating a new drug that has shown positive results in early tests of its ability to fight a rare and aggressive form of breast cancer.

8 Mar 2013

UNMC provides important genetic tool for scientists to better utilize library of mutant staph bacteria

Through the creation of a library of more than 2,000 mutant strains of the Staphylococcus aureus bacteria, the University of Nebraska Medical Center has provided an important tool for scientists around the world seeking answers for how to better deal with staph infections.

8 Mar 2013

Acceleron commences ACE-536 phase 2 study in beta-thalassemia

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced the initiation of a phase 2 study of its novel, investigational protein therapeutic, ACE-536, to treat patients with beta-thalassemia, a genetic hematologic disorder causing chronic and life-threatening anemia and serious complications affecting the spleen, liver and heart.

7 Mar 2013

High Court to consider whether drug company deals restrain trade

Generic drugs have dramatically changed the pharmaceutical and health-care landscape in the last 25 years and now account for about 80 percent of prescriptions in the United States, with lower prices for consumers and insurers.

7 Mar 2013

UCLA scientists discover new genetic risk factor for Alzheimer's disease

Scientists at UCLA have discovered a new genetic risk factor for Alzheimer's disease by screening people's DNA and then using an advanced type of scan to visualize their brains' connections.

7 Mar 2013

Pharmaceuticals News and Research

Bitter melon juice restricts ability of pancreatic cancer cells to metabolize glucose

Trans-Pacific Partnership (TPP) Agreement: an interview with Judit Rius, Médecins Sans Frontières

Chimerix receives FDA Fast Track designation for CMX001 to prevent CMV infection

Lithera commences LIPO-202 Phase 2b trial for reduction of subcutaneous fat

Sleep problems may be indicator of early Alzheimer's disease

Anti-cancer drug conjugates: an interview with Dr Andreas Menrad, CSO Ablynx and Dr Chris Martin, CEO Spirogen

Pneumococcal vaccine pre-clinical development supported by £0.2 million award from Biomedical Catalyst

Sosei commences SO-1105 Phase III trial in oropharyngeal candidiasis

FDA accepts Ampio’s Patient Outcome for Premature Ejaculation questionnaire

Armetheon plans to develop tecarfarin against prosthetic heart valves or chronic renal dysfunction

Drugs that combat ageing may be available within five years

Investigational treatment for ulcerative colitis (UC) and Crohn’s disease (CD) has Marketing Authorisation Application submitted

Animal robots help treat dementia

Global cancer problem ‘needs international solution’

UCR professor to better organize enzymes on electrodes to create nanoscale devices

Novel drug seems to increase effectiveness of usual chemotherapy against IBC

UNMC provides important genetic tool for scientists to better utilize library of mutant staph bacteria

Acceleron commences ACE-536 phase 2 study in beta-thalassemia

High Court to consider whether drug company deals restrain trade

UCLA scientists discover new genetic risk factor for Alzheimer's disease

Event guide: World ADC Asia eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence